Company Profile

CEO Message

We believe in the healing touch. We provide high quality medication in order to protect the health of our patients. We have dedicated our lives to medical research and to further the Pakistani pharmaceutical industry.

The company was built to serve and protect the interests of its patients, which we do through the sale, distribution and manufacture of our healthcare products since 2012.

CLARITY founded as a pharmaceutical Distributor, the firm now operates a wide number of business units covering the large spectrum of pharma business, from development, promotion and trading to logistics, the distribution and Marketing of healthcare products. CLARITY also maintain
liaisons with National and Multinational manufacturers. It is the exclusive distributor of Roche Pakistan Sandoz (Novarsit) and many other renowned companies and collaborator with GENOME, SHAROOQ and other companies on specific products. In 2019 CLARITY kicked off a deal with
ROTEX for a series of Oncology and Infectious disease products.

CLARITY has been characterized in Specialized medicines as one of the most dynamic pharmaceutical firms in Pakistan and is gradually becoming an important player in pharmaceutical Industry. Since 2012 the firm dedicates more than 15% of the annual turnover in investments and has developed a specialized workforce of dedicated people.

Who We Are

Our Introduction start with the world of CLARITY means honesty and
reliability that our slogan. CLARITY Biosciences is one of the nation’s fastest growing companies in the pharma industry. Over the past couple of years, CLARITY has carved out a name for itself in Pakistan for its reliable
and quality products. Every day, we re-evaluate what we have accomplished and try to improve on it, we are constantly researching new
methods in order to add to our current portfolio.

The company was built to serve and protect the interests of its patients, which we do through the sale, manufacture and distribution of our
healthcare products.

CLARITY has been working diligently in order to protect the lives of patients. We have grown from strength to strength since then, and are one of the leading pharmaceutical companies in Pakistan right now.

CLARITY market innovative state-of-the-art generic products with some of
them being unique. While the firm has been one of the first generic entrants in Colistimethate Sodium and Aprepitant and is becoming the
development champion on a number of molecules.

Under a dynamic management team and based on the expertise of its
team managers and leaders, CLARITY is implementing an aggressive strategy to remain a leader in the regional market and a complete reliable
partner for pharma services.

Our Values

Caring

We care about our people, we care about our customers and respect the values of the medical and pharmaceutical community. We are a company of professionals addressing our solutions to healthcare experts and wellinformed consumers. We want to return our profits to the society and the world of health, we want to invest in new solutions and develop products of the highest quality and effectiveness.

Growing

We are constantly growing, learning and improving, as we set ambitious goals and plan for the future. We are growing our workforce and knowledge resources, our products portfolio and our business units aspiring to become the market leader in Pakistan and in the region.

Globalizing

We aim at becoming an international firm within a local traditional context. We apply the international standards in quality, marketing ethics, pharma covigilance and customer support and establishing our presence as developers, traders and marketeer of top quality generic brands.

Diversifying

In 2017, CLARITY has successfully diversified its operations, from distribution and medical trading to the promotion of generic and onpatent products. In 2019 we launched more brands than any other company in our competitive field and in the years 2019-2020 our growth rate has placed us among the top performing healthcare firms, as we operate a wide set of business units.

Our History

2012

It all started in 2012 as CLARITY acquires legal entity as a Distribution company.

2014

CLARITY expands in medicine distribution and cooperates, with the companies Roche Pakistan, Eli Lilly & Co., Sandoz (Novartis), Atco Laboratories, CCL Pharmaceuticals, AJM Pharma, Amgomed Pharma and 23 different National & International Pharmaceutical companies distributions.

2017

CLARITY moves towards to an in-house development strategy, it obtains products, and establishes new departments for Marketing and Sales.

2019

CLARITY receives the award letters for its products from SKMCH, MSD SINDH, renowned atomic energy institutes KIRAN, CENAR, NORIN, SINOR, INOR etc.

2020

The ongoing quest for quality assurance of services / products leads to the acquisition of the Certificate of Authenticity for specialized products.

Business

Marketing

At CLARITY , we help build “Molecules into Brands” we work with our customers, strategically and pro-grammatically to accelerate, expand and extend the product life cycles markets through our portfolio of branded generics. We focus on new generations of drugs thereby ascending the value chain in the marketing and ultimately increase revenues from the sales of our products.

DISTRIBUTION & LOGISTICS

CLARITY is operating one of the best equipped and state of the
art logistics building of 2000 sq. ft in Karachi, including freeze conditions and red codes management systems, all monitored by a fully dig-itized monitoring system.

CLARITY has been undertaking distribution deals and contracts for large-scale clients and local firms. A full set of services (such as, Logistics Management, Distribution, Sticker Labelling, Warehousing, Order Management, Transactions, Payment Collection, Accounting Support, Customized Transport and Drugstores Hub) guarantees the clients’ satisfaction and regular inspections from multinational firms certifies the quality of installations, the robust procedures and the development of an excellence experience over the years.

Business Units

Oncology

A top earning performer, managed by an experienced team in oncology products, the business unit has been focusing on cancer treatment and Chemotherapy products. 2021 will be a year of important launches and expansion plans for this Business Unit as the launches of number of products related to oncology are on its way.

Thalassemia & Hemotology

With a portfolio of Four (4 ) products currently working as a company with largest range in thalassemia . Our aim is to provide the best quality treatment on the lowest economical price to serve the suffering children.

Infectious Diseas

Leading the market with the best quality products , and currently enjoying the big chunk of Colistimethate sodium in renowned Hospital units throughout Pakistan

Nephrology & Transplat

J u s t ma r k e d t h e p r e s e n c e i n t h i s p o r t f o l i o w i t h o n e immunosupressent, but there is long pipe line of innovative drugs in 2021 to lead the market from front.

Partnership

CLARITY invests in stable partnerships with multinational firms, se-lected regional clients and networks in the healthcare sector. Since 2012, the company has developed more than twenty (20) profitable contracts and constantly achieves top evaluations from its product and strategic partners. Other strategic partnerships include the exclusive distribution of products for foreign and Pakistani firms.

Key Partners

logoblueeng-1

BELMEDPREPARATY is the number one ranked pharmaceutical in BELARUS since last 10 years, and our partner since last 3 years for oncology products.

genome

GENOME pharma ranked in top 80 pharma companies in a year (2019-2020) Pakistan, and manufacturing nephrology and thalassemia products for CLARITY .

rotex
ROTEX pharma has got state of the art BIOTECH plant, and since 2019 they are our partners and manufacturing a bulk of oncology, thalassemia and infectious disease products for CLARITY .
evoluyion
Evolutaion Pharma is a manufacturing facility for new molecules for CLARITY .
sharooq
Exclusive Partner for the product EFESIR (Deferasirox).
sp-accire
Exclusive Partner CLARITY.

Development

CLARITY is investing more than 15% of its annual in-come on new products, technologies and infrastructure in order to secure sustainable and constant growth rates for then next five (5) years. An aggressive development plan is divided in four (4) key directions:

New Partnerships

We are licensing-in a wide number of products in order to strengthen our range of generics brands in oncology, Infectious Diseases, Thalassemia, Nephrology, Anesthesia and urology while also attracting business projects in collaboration with multinational firms and international companies. In 2016 and 2017 CLARITY will announce a se-ries of collaborations that will grow its turnover by 25%% (est.).

Product Development

CLARITY has recent-ly kicked-off operations of its new Business Development through cotract agreements with European and Korean principles. The purpose is to get innovative products that can help the community without hurting economy.

New Manufacturing Site

At the heart of CLARITY ’s development strategy lays the ‘greenfield’ project of a new manufacturing unit in Pakistan. The development team is working on the completion of this project by 2025 and the fully modern FDA standards unit will include manufacturing capacity on solid forms, soft gelatin capsules and sterile formulations.

Innovative Treatments

CLARITY is a generic firms investing in original treatments and added-value products that enhance and improve the therapeutic results. Our ‘better society’ development plan focuses on addiction treatment, cheap medication for life threatening diseases and socially responsible ways of developing health solutions for all.

Products

Future Pipeline

2nd QUARTER 2021-2022

  • Propofol
  • Paricalcitol
  • Liprolide Acitate
  • Retuximab 100mg, 500mg
  • Pegfilgrastim
  • Liposomal Doxorubicin 20mg, 50mg
  • Paclitaxel 30mg, 100mg, 150mg, 300mg
  • Heparin (Bovine)